Skip to content

Cash ratio at other companies

Pfizer logo
PfizerPFE
0.1×0.0×
Merck & Co. logo
Merck & Co.MRK
0.2×-0.1×
AbbVie logo
AbbVieABBV
0.2×+0.1×
Insmed logo
InsmedINSM
1.6×-0.1×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
0.2×-0.8×
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
2.5×-1.4×

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio21.1×+18.7×

Where this comes from

Calculated from Innoviva, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s cash ratio?
Innoviva, Inc. (INVA) reported cash ratio of 16.5× in Q1 2026.
How has Innoviva, Inc.'s cash ratio changed year-over-year?
Innoviva, Inc.'s cash ratio increased by 1113.6% year-over-year, from 1.4× to 16.5×.
What is the long-term trend for Innoviva, Inc.'s cash ratio?
Over 5 years (2020 to 2025), Innoviva, Inc.'s cash ratio has grown at a -22.8% compound annual growth rate (CAGR), from 40.3× to 11.1×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.